Leverages drug target to develop and commercialize therapies for auto-immune diseases
Investors 1
| Date | Name | Website |
| - | Foothill V... | foothill.v... |
Mentions in press and media 3
| Date | Title | Description | Source |
| 19.07.2023 | Avotres Presents Clinical Data for AVT001, a Novel Dendritic... | • AVT001 is an investigational autologous dendritic cell-based vaccine for the treatment of new onse... | einpresswi... |
| 09.12.2022 | Avotres Announces Achieving Primary Endpoint of its Phase 1/... | - AVT001 met its primary endpoints (safety) and demonstrated a strong efficacy signal at the primary... | einpresswi... |
| - | Avotres | “Avotres Inc. is a private biotechnology company developing breakthrough therapeutic solutions for i... | fastfounde... |